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Preoperative Imaging of Charcot Neuroarthropathy in Diabetic Patients:
Comparison of Ring PET, Hybrid PET, and Magnetic Resonance Imaging
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M.D.; Stefan Dresel, M.D.
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ABSTRACT
Introduction: The treatment of Charcot neuroarthropathy
in the feet of diabetic patients has undergone fundamental
changes in the last few years. Formerly, treatment was
almost exclusively limited to nonoperative measures;
since the late 1990s, however, current practice has shifted
to early, stage-appropriate surgical therapy. The objective
of this prospective study was to investigate the value of
two types of positron emission tomography (PET) in the
preoperative evaluation of diabetic patients with Charcot
foot deformities. Materials and Methods: Ring [18F]FDG (2-
fluoro-2-deoxy-glucose) and hybrid PET were compared
to magnetic resonance imaging (MRI). MRI, ring PET, and
hybrid PET imaging were used as part of the preoperative
evaluation of 16 patients with type II diabetes mellitus.
The diagnosis of Charcot neuropathy of the foot requiring
operative treatment had been made on the basis of
clinical and radiographic criteria. Results: Of 39 Charcot
lesions confirmed at surgery, 37 were detected by ring
PET, 30 by hybrid PET, and 31 by MRI. Conclusions:
PET (ring or hybrid) can be used in the evaluation of
patients with metal implants that would compromise the
accuracy of MRI. Another advantage of PET is its ability
to distinguish between inflammatory and infectious soft-
tissue lesions, and between osteomyelitis and Charcot
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neuroarthropathy. The differentiation between Charcot
neuroarthropathy and florid osteomyelitis provides the
surgeon with important additional information that often
is unavailable from MRI. Because it provides important
additional data, ring PET may be preferable to radiography
and MRI in the preoperative evaluation of patients
with Charcot neuroarthropathy of the foot. Hybrid PET,
because of its poorer resolution compared to ring PET,
appears less suitable for routine clinical application.
Key Words: Bone Detritus; Charcot Neuroarthropathy;
Diabetic Neuropathy; Magnetic Resonance Imaging;
Positron Emission Tomography
INTRODUCTION
Charcot neuroarthropathy is a late complication of
diabetes mellitus. According to the definition proposed
in 1868 by J. M. Charcot, it consists of a non-
infectious destruction of single or multiple bone and
joint structures in patients with concomitant neuropathy,
most often affecting the skeletal structures of the foot.4,6
Autonomic neuropathy results in local hyperperfusion
with pathologic innervation of the vascular musculature.
This, in turn, leads to maximal vascular dilatation with
resultant absorption of bone (bone detritus). Disease
progression is accompanied by associated sensory
and sensomotor neuropathy, with reduced touch and
pain sensation. Chronic malpositioning of the limb with
associated microtrauma and macrotrauma results in
long-term destruction of both soft-tissue and bony
structures (Figure 1).11
If Charcot neuroarthropathy of the foot is not diag-
nosed early and treated appropriately, physical disability
usually occurs within an average of 10 years.6,12 World-
wide, foot-related morbidity is one of the leading
reasons for in-patient hospital admissions of patients
with diabetes mellitus and is associated with a
890
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Fig. 1: A 65-year-old male with a 23-year history of type-II diabetes
mellitus and pain in both feet. Radiograph shows damage to the arch
of the foot resulting in a rocker-bottom deformity.
corresponding financial impact on national health-
care systems.3,5 These facts have contributed to
fundamental changes in the management of Charcot
neuroarthropathy of the foot in the last few years.
Formerly, treatment was almost exclusively limited to
nonoperative measures; since the late 1990s, however,
current practice has shifted to early, stage-appropriate
operative.3,7 Although nonoperative treatment is still the
standard treatment of the disease in its initial stages
(Eichenholtz stages I and II),2 operative management
is considered much earlier in the course of the
disease. Indications for surgery include soft-tissue
infections, joint instability, recurring collapse of the
foot, and foot deformities. To determine if surgery is
indicated, the surgeon must consider, in addition to
anatomic conditions in the limb, the extent of osseous
involvement. Preoperative evaluation seeks to establish
anatomic conditions in the limb using conventional
radiography (Figure 1). If radiographic findings are
inadequate, computed tomography (CT) using a thin-
layer technique can be added. Because of the frequency
of poor wound healing and recurrent disease in diabetic
patients, it is increasingly important to detect both early-
stage Charcot lesions and secondary inflammatory
changes in bony and soft-tissue structures.
Diagnostic imaging techniques also are essential to
differentiate between Charcot neuroarthropathy and
osteomyelitis because their surgical treatments are very
different. Often, because clinical features alone are
not sufficient to distinguish between the two, contrast
enhanced magnetic resonance imaging (MRI) is used.
The bone marrow edema that is typical in patients with
diabetes can make it difficult to distinguish between
unspecific coincidental reactions in adjacent bone and
early-stage Charcot neuroarthropathy.10,14 The efficacy
of MRI also is compromised by the presence of metal
artifacts in patients who have had earlier operations.
The objective of this prospective study was to
determine the value of positron emission tomography
(PET) in the preoperative evaluation of diabetic patients
with Charcot neuroarthropathy of the foot and to
compare the efficacy of ring PET and hybrid PET with
that of MRI.
METHODS AND MATERIALS
Sixteen patients (nine males, seven females) with
an average age of 60.1 years (±10 years) had both
MRI and PET scaning between June, 2001, and
August, 2002, as part of their preoperative evalua-
tions of Charcot foot conditions. All 16 patients had
type II diabetes mellitus. The decision to proceed
to operative treatment of their Charcot foot deformi-
ties was based on clinical and radiographic findings.
No more than 1 week elapsed between preoperative
radiographic examination and nuclear medical imaging.
PET examinations were conducted after a minimum
12-hour fasting period. The radiopharmaceutical 2-
[18F]-fluorodeoxyglocose (FDG) was injected (250 to 370
MBq) immediately after blood glucose levels were deter-
mined. In all patients, ring PET scanning was begun 45
minutes after injection of the radiopharmaceutical and
was followed immediately by hybrid PET scanning.
Ring PET examinations were done with a Siemens
ECAT EXACT HR+ (Siemens/CTI, Knoxville, TN). The
emission data was acquired in 3D mode beginning at
the tips of the toes and proceeding proximally (five
bed positions; 8 minutes per bed position; field of
view per bed position, 15.5 cm). The acquired data
was then subjected to iterative reconstruction. Datasets
were reoriented in transverse, coronal, and sagittal
projections.
The hybrid PET examinations were done with
a Marconi AXIS γ -PET2 scanner (Marconi Medical
Systems, Cleveland, OH) in list mode using an axial
filter. The acquisition of two bed positions (35 minutes
per bed position; field of view per bed position, 42 cm)
began at the tips of the toes. Data were rebinned in a
128× 128 matrix and iteratively reconstructed. Trans-
verse, coronal, and sagittal layers were generated.
MRI examinations were done with a Siemens
Harmony scanner (1.0 Tesla field strength; Siemens
AG, Erlangen, Germany) using a standardized protocol
with a sagittal short time inversion recovery (STIR)
sequence and subsequent coronal T1 and T2-weighed
sequences. After intravenous administration of contrast
medium (gadolinium DTPA, 0.2 ml/kg body weight), a
fat-suppressed T1-weighted sequence in coronal and
sagittal projections was acquired.
All findings were interpreted using a special eval-
uation form by two experienced examiners blinded
to the results of the other imaging method. The
bony structures of the foot were subdivided into six
subgroups: calcaneus, talus, navicular bone, cuboid
bone, cuneiform bones and metatarsals. Also evalu-
ated were the soft-tissue structures of the affected feet
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and the intraarticular spaces, particularly the transverse
tarsal articulation (Chopart line) and Lisfranc articula-
tion, both of which are frequently affected in Charcot
foot deformities (Table 1).
Findings at subsequent surgery were compared to
those of the three imaging techniques.
RESULTS
Sixteen diabetic patients with Charcot neuroarthro-
pathy of the foot had MRI, ring PET, and hybrid
PET examinations as part of their preoperative eval-
uations. Thirty-nine lesions consistent with Charcot
neuroarthropathy were identified by diagnostic imaging
and confirmed at surgery, including 24 osseous
lesions with bone detritus formation typical of Charcot
neuroarthropathy without evidence of osteomyelitis; six
secondary, circumscribed foci of inflammation in adja-
cent soft tissue with no evidence of infection; and nine
lesions with inflammatory tissue along typically affected
articulations such as those in the ankle and at the
Chopart and Lisfranc articulations.
Of the 39 lesions confirmed at surgery, 37 (95%)
were successfully identified by ring PET. All lesions
involving inflammation of soft tissue or articulation
lines were correctly identified. In evaluating disease
involving the bones, only two small sites of detritus
formation escaped detection. In general, areas of
detritus formation exhibit only moderately increased
glucose metabolism and at visual interpretation usually
are not typical of acute osteomyelitis or soft-tissue
infection. The average standardized uptake value (SUV)
was 1.8 (range 0.5 to 4.1). It also was easy to differentiate
between disease foci limited to the bone and secondary
soft-tissue involvement. The exact localization of lesions
is presented in Table 1.
In contrast, hybrid PET successfully identified only 30
lesions (77%). Particularly prone to evade detection
were small osseous lesions involving the talus or
calcaneus and the tarsals. Inflammatory processes in
typically affected articulations were detected with equal
efficacy by both hybrid and ring PET, whereas two
smaller soft-tissue lesions were not correctly diagnosed
by hybrid PET.
MRI correctly identified 31 of the 39 lesions (79%)
confirmed by surgery. This lower detection rate can be
explained by the inclusion of three patients with metal
implants in whom the resulting extensive metal artifacts
interfered with the detection of six lesions. If these three
patients are excluded, there is little difference between
MRI (31 of 33 lesions correctly detected, 94%) and ring
PET (32 of 33 lesions, 97%). With the exception of a
small area of bone detritus formation, MRI successfully
identified all sites of osseous, articulation-line, and soft-
tissue inflammation.
Because of significant contrast medium uptake in the
T1-weighted sequences and the bone marrow edema
in the STIR sequences, it was not always possible to
definitively differentiate between infected bone detritus
and an osteomyelitic lesion or between soft-tissue
inflammation and soft-tissue infection.
All 16 patients had type-II diabetes mellitus. Despite
a minimum of 12 hours of fasting before examination,
the blood glucose concentrations measured before
administration of the radiopharmaceutical ranged from
92 to 254 mg/dl (average 153.8 mg/dl). A comparison
of PET examinations obtained from patients with blood
glucose concentrations within the normal range (80 to
120 mg/dl) and from those with blood sugar levels of
more than 200 mg/dl revealed better image quality in
the group with the lower blood glucose concentrations.
There was, however, no difference in the rate of
detecting Charcot lesions between the two groups using
either PET modality.
DISCUSSION
In diabetic patients with Charcot neuroarthropathy,
the decisive issue to be clarified at preoperative eval-
uation, besides identification of the osseous structures
involved, is the exclusion of acute inflammatory or infec-
tious disease processes, such as osteomyelitis. The
Table 1: Surgical Findings Compared to the MRI and PET Findings
Talus/
Calcaneus
Navicular/Cuboid/
Cuneiform Metatarsals Articulations
Soft
tissue 
Surgical findings 11 10 3 9 6 39
Ring PET 10 9 3 9 6 37
Hybrid PET 8 7 2 9 4 30
MRI 8 8 3 7 5 31
Findings in 16 patients with diabetic Charcot neuroarthropathy. The findings of diagnostic imaging methods are correlated with surgical
findings. Lesions detected by imaging methods outside of the surgical field are not included in the table.
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extent of bony destruction is determined with radio-
graphy and thin-layer computed tomography (CT).6
While these methods are considered sufficiently accu-
rate for routine clinical use, conventional radiography
often misses early-stage Charcot lesions, and findings
may be normal during the acute phase.12 For this reason
and because of the frequency of disease recurrence
and wound-healing disorders in patients with Charcot
neuroarthropathy, there has been increasing recognition
of the importance of distinguishing between this entity
and infectious processes of the bone and adjacent
soft tissues.
At present, this is done almost exclusively by
contrast-enhanced MRI. The current international liter-
ature reports generally good results with this moda-
lity.10,14 However, overestimation of the extent of
inflammation caused by associated edema of adjacent
osseous and soft-tissue structures can cause difficulty
in interpreting MRI findings of bone marrow edema
for differentiation between lesions typical of Charcot
neuroarthropathy and those secondary to foci of infec-
tion, such as osteomyelitis.
Our results indicate that both ring PET and MRI are
effective in the preoprative detection of small, inflam-
matory, non-infectious Charcot lesions (Figure 2). The
most important limitation of MRI is its restricted effi-
cacy in patients with metal implants. In the present
study, all but one of the lesions confirmed during
surgery were successfully identified by ring PET, the
exception being a small area of osseous involvement of
the talus near the Chopart articulation. Both methods,
however, identified the Chopart articulation as a site of
disease involvement in this patient, and the failure to
identify the additional bone detritus did not markedly
affect preoperative planning. Our MRI findings corre-
spond with current published data describing the early
detection of Charcot lesions with MRI.6,8,10 Our expe-
rience, however, also corresponds to reports of the
difficulty of interpreting MRI findings because of the
overestimation of the extent of inflammation based on
associated edema in adjacent and nearby osseous and
soft-tissue structures.
In patients who have metal implants, artifact formation
normally precludes adequate MRI examination. Our
study showed that ring PET or hybrid PET can
supply adequate information in such patients, as
confirmed by surgical findings (Figure 3). An additional
advantage of PET is the capacity to differentiate
between inflammatory and infectious soft-tissue lesions
and between Charcot lesions and osteomyelitis on
the basis of glucose metabolism. Charcot lesions at
a mean SUV of 1.8 (range 0.5–4.1) can be distinguished
from florid osteomyelitis, which typically has a much
higher SUV.13 This differentiation on the basis of
increased glucose metabolism provides the surgeon
with important additional data that often is not reliably
provided by MRI.
Other imaging methods that have been compared
with conventional radiography or MRI for evaluation
of Charcot neuroarthropathy include three-phase bone
scanning, indium-111 white blood cell (WBC) scintig-
raphy and technetium-99m hexamethylpropyleneamine
oxine (HMPAO) WBC scintigraphy. Maugendre and
Pioror9 showed that, in the evaluation of patients
Fig. 2: A 69-year-old male with 25-year history of type-II diabetes mellitus. A, MRI fat-suppressed T1-weighted sequence; B, MRI STIR sequence;
and C, PET, all in sagittal projection. Evidence of typical Charcot lesions is present in all imaging methods. MRI overestimates the extent of
inflammation because of adjacent and associated edema.
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Fig. 3: A 58-year-old female with a 4-year history of type-II diabetes mellitus and previous surgery involving the metatarsals of the left foot. A,
Radiography shows only the metal implant but no new destructive changes. B, Because of the extensive metal artifacts, adequate interpretation
of MRI findings is impossible. C, PET shows typical Charcot lesions in the previous surgical zone at the Chopart articulation.
with Charcot neuroarthropathy of the foot, comparable
results were obtained by bone scans and conventional
radiography. Lipman et al.8 Reported that MRI was
more effective in the detection of osteomyelitis foci,
particularly in the tarsals. Leukocyte scintigraphy has
been proposed as a method for confirming or excluding
osteomyelitis when other imaging methods suggest its
presence.8,9,15 Our results, however, showed both PET
and MRI to be effective in detecting osteomyelitis.
Compared to MRI and ring PET, hybrid PET had a
lower sensitivity in detecting smaller bone and soft-
tissue lesions (diameter of less than 1 cm). In addition
to several osseous lesions, some sites of inflammation
in soft tissues were missed. While hybrid PET may be
acceptable in the evaluation of patients with Charcot
neuroarthropathy of the foot, it appears to be less
suitable as part of preoperative planning than ring PET,
which is better able to detect inflammatory lesions.
Despite the very high blood glucose concentrations
measured in some patients before administration of the
radiopharmaceutical, there was little difference in the
detection of Charcot lesions between patients whose
blood sugar levels were within normal limits and those
with elevated blood glucose levels.
Our data demonstrated that PET provides results
comparable to MRI in the preoperative evaluation of
patients with Charcot neuroarthropathy. In addition,
PET offers the advantages of being unaffected by
metal implants and being able to differentiate between
inflammatory and infectious soft-tissue lesions and
between osteomyelitis and Charcot lesions on the basis
of glucose metabolism with increased FDG uptake
(SUV). Because of this ability to provide complementary
imaging data, ring PET should be considered as
an adjunct to conventional radiography and MRI in
the preoperative evaluation of patients with Charcot
neuroarthropathy of the foot. Hybrid PET, because of
its poorer resolution than ring PET, appears less suitable
for routine clinical use.
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